Ascendis Pharma A/S is a Denmark‑based biopharmaceutical company operating within the life sciences and biotechnology sector. The Company scope of activity includes discovery, development, and commercialization of innovative therapies for rare diseases and serious chronic conditions with significant unmet medical needs where a clinically validated parent drug or pathway is suitable to company technologies. Ascendis Pharma A/S focuses on the endocrinology area and has a pipeline of three independent rare disease product candidates, such as Growth Hormone Deficiency (GHD), Hypoparathyroidism and Achondroplasia. The second therapeutic area is oncology, where the company focuses immunotherapy to targeted therapies.
Back to dashboard
Company Information
About this company
Key people
Albert Cha
Independent Chairman of the Board
Donovan Wu
Executive Vice President, U.S. President
Mads Bodenhoff
Senior Vice President, Head of Finance and Principal Accounting Officer
Lisa Bright
Independent Director
William Carl Fairey
Independent Director
Lars Holtug
Independent Director
Siham Imani
Independent Director
Jan Moller Mikkelsen
President, Chief Executive Officer, Executive Director, Member of the Executive Board
Scott T. Smith
Chief Financial Officer, Executive Vice President, Member of the Executive Board
Lotte Soenderbjerg
Executive Vice President, Chief Administrative Officer, Member of the Executive Board
Michael Wolff Jensen
Executive Vice President, Chief Legal Officer, Member of the Executive Board
Flemming Steen Jensen
Executive Vice President, Product Supply and Quality
Aimee Shu
Executive Vice President, Chief Medical Officer
Stina Singel
Executive Vice President, Head of Clinical Development, Oncology
Kennett Sprogoee
Executive Vice President, Head of Innovation and Research
Click to see more
Key facts
- Shares in issue66.71m
- EPICASND
- ISINDK0060615755
- LocationDenmark
- SectorHealthcare
- IndustryBiotechnology & Drugs
- Market cap$14.96bn
- Employees1,189
- ExchangeNASDAQ
- Index
- Website
Data policy - All information should be used for indicative purposes only. You should independently check data before making any investment decision. HL cannot guarantee that the data is accurate or complete, and accepts no responsibility for how it may be used. Overview data is sourced from Refinitiv.